Doccol是一家美國生物技術公司，從解決生物研究中的實際問題開始。2004年，Doccol發(fā)現(xiàn)了實驗性卒中研究的關鍵問題之一是卒中模型的質量不一致，因此通過提供標準化的封堵器，即硅橡膠涂層單絲，用于大腦中動脈閉塞（MCAO），為此提供了解決方案。這些MCAO封堵器深受中風科研人員的喜愛，并被命名為“MCAO縫合線"。 我們精致的硅橡膠涂層單絲是專門為誘導MCAO腔內燈絲模型而設計制造的，該模型已被廣泛用于體內實驗性腦卒中研究。使用 Doccol MCAO 縫合線誘導卒中模型將通過減少不全部閉塞和顱內出血的發(fā)生來提高模型質量。使用Doccol MCAO縫合線，您將能夠實現(xiàn)高度一致的梗死以及低死亡率。除了認可的產品質量外，Doccol還為MCAO縫合線提供了種類繁多的縫合線，旨在滿足中風研究人員的各種需求。多年來，我們的MCAO縫合線一直被中風研究人員優(yōu)選用于誘導中風模型。據(jù)報道，使用Doccol MCAO縫合線誘導MCAO模型能夠將梗死體積的標準偏差降低到其相應平均值的5%; 這種建模方法正在成為確保MCAO模型最高質量的新標準。欲了解更多信息，中國客戶請聯(lián)系美國Doccol在中國的總代理靶點科技。

2010年，Doccol注意到大多數(shù)實驗室進行的微血管導管插入術對于血液檢測和藥物輸送都不方便。這些“微導管"有一個需要針頭連接的過渡管，當壓力高時可能會斷裂，并且可能會意外刺入操作員的手指，然后才能連接到合成器。這些導管也有很大的內部容積，必須處理才能輸送藥物。Doccol 提供專門設計的微導管，用于提高嚙齒動物血液采樣、藥物輸送、小流速液體轉移和生理監(jiān)測的性能、質量和生產率，其中需要侵入性血管通路。我們的微導管連接到工業(yè)標準的魯爾鎖或旋塞閥，因此消除了過渡管和針頭連接，也大大減少了內部體積。Doccol 為所有常見部位的血管插管提供了足夠的微導管選擇，例如尾靜脈、股靜脈、頸靜脈和臂靜脈和動脈，以及頸靜脈。

在Doccol多年來致力于中風研究期間，Doccol 還開始提供精心挑選的基本顯微手術工具和設備，并于 2019 年開發(fā)了其不同的基于 Arduino 的 PID 溫度控制器。這些工具和設備可確保您的實驗性中風研究具有高質量和高生產率。

Doccol is a biotech company that started from solving real problems in biological research. In 2004, Doccol identified one of the key problems in experimental stroke research is the inconsistent quality of stroke models, and thence provided a solution for this by offerring standardized occluders, the silicone rubber-coated monofilaments,  for middle cerebral artery occlusion (MCAO). Those MCAO occluders  were liked very much by stroke reaearchers and given the name "MCAO sutures".  Our delicate silicone rubber-coated monofilaments are specially designed and manufactured for inducing the intraluminal filament model of MCAO, which has been widely used for in vivo experimental stroke studies. Using Doccol MCAO sutures for inducing stroke models will improve your model quality by reducing the occurrence of both the incomplete occlusion and the intracranial bleeding. With Doccol MCAO sutures, you will be able to achieve a highly consistent infarct as well as a low mortality rate. In addition to the super product quality, Doccol provides MCAO sutures with a great variety that was designed to meet the diverse demand from stroke investigators. For many years our MCAO sutures have been preferably selected by stroke investigators for inducing stroke models. Using Doccol MCAO sutures for inducing MCAO models has been reported to be able to reduce the standard deviation to 5% of its corresponding mean value as for infarction volume; and this modeling method is becoming a methodological new standard for ensuring the highest quality of MCAO models. For more information please read Doccol Made a Difference in Stroke Modeling.

In 2010, Doccol noticed that microvascular catheterization procedures performed in most laboratories are inconvinient for both blood testing and drug delivery. Those "microcatheters" have a transition tubing requiring a needle connection, which may break when pressure is high, and may accidentally puncture into the operator's finger, before it can be connected to a synringe. These catheters also have a large inner volume that has to be dealt with for drug delivery. Doccol offerred specially designed microcatheters for improving performance, quality and productivity in rodent blood sampling, drug delivery, small flow rate liquid transferring, and physiological monitoring, in which invasive vascular access is necessary. Our microcatheters are permanently connected to an industrial standard Luer lock or stopcock, therefore, eliminated the transitional tubing and needle connection and also dramatically reduced inner volume. Doccol provides sufficient choices of micro catheters for vascular cannulation in all common locations, such as the tail, femoral, carotid, and brachial veins and arteries, and also the jugular veins.

During years of our dedicated services in stroke research, Doccol also started to provide our carefully-selected essential microsurgical tools and devices, and in 2019 Doccol developed its unique Arduino-based PID temperature controllers. These essential tools and devices ensure your experimental stroke research with high quality and high productivity.

靶點科技（北京）有限公司（Target Technology (Beijing) Co.,Ltd.），成立于2016年，是由一群來自歐洲荷蘭的留學海歸和高校及研究所博士人員創(chuàng)辦的生物高科技公司。公司基于四個平臺技術TargoSome^®（脂質體靶向技術），TargoChem^®（化合物靶向技術），TargoAnti^®（抗體靶向技術）和TargoNano^®（納米靶向技術），研發(fā)了靶向細胞的遞送系統(tǒng)。

公司注重轉化醫(yī)學，強化“Bench-to-Bedside"的基礎產品開發(fā)。目前，靶點科技已經(jīng)成為單核巨噬細胞系統(tǒng)研究領域的樹立良好口碑，能夠給研究人員提供各種模擬人類疾病的動物模型的制備，公司團隊對單核巨噬細胞系統(tǒng)有著深刻的認識和理解，從標記，分離，富集，純化，培養(yǎng)和細胞清除，形態(tài)識別等提供一整套綜合解決方案。

基于對靶點科技（北京）有限公司的認同，自2022年11月29日期，靶點科技被美國Doccol公司授權為中國總代理?？蛻敉ㄟ^靶點科技購買美國Doccol公司的產品，質量可靠，渠道合法，售后無憂。大腦中動脈阻塞(MCAO)造模是研究缺血性腦卒中的經(jīng)典動物模型，Doccol是MCAO造模國際廣泛使用的栓線品牌，文獻數(shù)以萬計。

靶點科技始終秉承“Bench to Bedside"的出發(fā)點，“專業(yè)⁺專注⁺"的服務宗旨，以“Hit Your Target^®"為目標， 竭力為客戶提供“Proven and Published^®"的一攬子綜合解決方案，將為實現(xiàn)這一美好愿景而努力奮斗。